Drug intelligence / Profile preview

human umbilical cord mesenchymal stem cell-derived exosomes (long non-coding RNA-9969 knockdown)

Development stage: Preclinical
Modality: Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Human umbilical cord mesenchymal stem cell-derived exosomes (hUC-MSC-Exos) with long non-coding RNA-9969 (lncRNA-9969) knockdown are specialized extracellular vesicles used to investigate the molecular mechanisms of stem cell-based therapies in Alzheimer's disease. Research indicates that lncRNA-9969 is a critical component of the hUC-MSC exosomal cargo, providing neuroprotection by modulating microglial dysfunction, reducing neuroinflammation, and enhancing neuronal autophagy. By specifically knocking down lncRNA-9969, these modified exosomes serve as a research tool to demonstrate that the therapeutic efficacy of MSC-exosomes against Alzheimer's pathology—including lipid dyshomeostasis and pyroptosis—is dependent on this specific long non-coding RNA. This agent is currently in the preclinical development stage for the treatment of neurodegenerative diseases.

Other names: hUC-MSC-Exos (lncRNA-9969 knockdown)hUC-MSC-derived exosomes (lncRNA-9969 knockdown)

Beyond the preview

Go deeper on human umbilical cord mesenchymal stem cell-derived exosomes (long non-coding RNA-9969 knockdown).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord mesenchymal stem cell-derived exosomes (long non-coding RNA-9969 knockdown).

Explore the full profile